Co-administration of metformin and N-acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI

International Journal of Fertility and Sterility

Volumn 8, Issue 2, 2014, Pages 119-128

  Cheraghi, Ebrahim ^a   Soleimani Mehranjani, Malek ^a   Shariatzadeh, Mohammad Ali ^a   Nasr Esfahani, Mohammad Hossein ^b   Ebrahimi, Zahra ^c  

^a ARAK UNIVERSITY   (Iran)

^b ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Insulin Resistance; Metformin; N Acetyl Cysteine; Oxidative Stress; Polycystic Ovary Syndrome

Indexed keywords

ACETYLCYSTEINE; BUSERELIN; BUSERELIN ACETATE; CHOLESTEROL; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; MALONALDEHYDE; METFORMIN; MUELLERIAN INHIBITING FACTOR; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE SULFATE; PROLACTIN; RECOMBINANT FOLLITROPIN; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AMENORRHEA; ARTICLE; BODY MASS; COLORIMETRY; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLICULAR ASPIRATION; GLUCOSE BLOOD LEVEL; HIRSUTISM; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSVAGINAL ECHOGRAPHY; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 84904131707     PISSN: 2008076X     EISSN: 20080778     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995; 333(13): 853-861.
2. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod update. 2009; 15(4): 477-488.
3. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008; 10: e3.
4. Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician. 2009; 79(8): 671-676.
5. Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009; 30(1): 1-50.
6. Eisenhardt S, Schwarzmann N, Henschel V, Germeyer A, Von Wolff M, Hamann A, et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2006; 91(3): 946-952.
7. Norman RJ. Editorial: Metformin--comparison with other therapies in ovulation induction in polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89(10): 4797-4800.
8. Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod. 2005; 20(4): 894-899.
9. Fulghesu AM, Ciampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril. 2002; 77(6): 1128-1135.
10. Ammon HP, Müller P, Eggstein M, Wintermantel C, Aigner B, Safayhi H, et al. Increase in glucose consumption by acetylcysteine during hyperglycemic clamp. A study with healthy volunteers. Arzneimittelforschung. 1992; 42(5): 642-645.
11. Lappas M, Permezel M, Rice GE. N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. J Clin Endocrinol Metab. 2003; 88(4): 1723-1729.
12. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst (e) inemia in humans. Circulation. 1999; 100(11): 1161-1168.
13. De Flora S, Izzotti A, D'Agostini F, Balansky RM. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis. 2001; 22(7): 999-1013.
14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1): 19-21
15. Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010; 16(3): 231-245.
16. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6): 774-800.
17. Elnashar A, Fahmy M, Mansour A, Ibrahim K. N-acetyl cysteine vs. metformin in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective randomized controlled study. Fertil steril. 2007; 88(2): 406-409.
18. Checa MA, Requena A, Salvador C, Tur R, Callejo J, Espinós JJ, et al. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update. 2005; 11(4): 375-390.
19. Yarali{dotless} H, Yi{dotless}ldi{dotless}z BO, Demirol A, Zeyneloǧlu HB, Yiǧit N, Bükülmez O, et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod; 17(2): 289-294.
20. Rizk AY, Bedaiwy MA, Al-Inany HG. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 2005; 83(2): 367-370.
21. Morin-Papunen LC, Koivunen RM, Tomás C, Ruokonen A, Martikainen HK. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998; 83(7): 2566-2568.
22. Mendonça HC, Montenegro RM Jr, Foss MC, Silva de Sá MF, Ferriani RA. Positive correlation of serum leptin with estradiol levels in patients with polycystic ovary syndrome. Braz J Med Biol Res. 2004; 37(5): 729-736.
23. Krassas GE, Kaltsas TT, Pontikides N, Jacobs H, Blum W, Messinis I. Leptin levels in women with polycystic ovary syndrome before and after treatment with diazoxide. Eur J Endocrinol. 1998; 139(2): 184-189.
24. Singh B, Panda S, Nanda R, Pati S, Mangaraj M, Sahu PK, et al. Effect of metformin on hormonal and biochemical profile in PCOS before and after therapy. Indian J Clin Biochem. 2010; 25(4): 367-370.
25. Reddy PS, Rani GP, Sainath SB, Meena R, Supriya Ch. Protective effects of N-acetylcysteine against arsenic-induced oxidative stress and reprotoxicity in male mice. J Trace Elem Med Biol. 2011; 25(4): 247-253.
26. Diamanti-Kandarakis E, Kandaraki E, Christakou C, Panidis D. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obes Rev. 2009; 10(4): 431-441.
27. Salehpour S, Tohidi M, Akhound MR, Amirzargar N. N acetyl cysteine, a novel remedy for poly cystic ovarian syndrome. Int J Fertil Steril. 2009; 3(2): 66-73.
28. Sabuncu T, Vural H, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001; 34(5): 407-413.
29. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003; 80(1): 123-127.
30. Shyu KG, Chen SC, Wang BW, Cheng WP, Hung HF. Mechanism of the inhibitory effect of atorvastatin on leptin expression induced by angiotensin II in cultured human coronary artery smooth muscle cells. Clin Sci. 2012; 122(1): 33-42.
31. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease response to therapeutic interventions. Circulation. 2008; 117(25): 3238-3249.
32. Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Çakir N, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005; 20(12): 3333-3340.
33. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005; 20(7): 1820-1826.